2. Membrane Transporter/Ion Channel Neuronal Signaling
  3. TRP Channel
  4. AG1529

AG1529 is a TRPV1 inhibitor and capsaicinoid-based soft agent with a human TRPV1 IC50 of 0.9-0.93 μM. AG1529 reversibly blocks capsaicin-evoked TRPV1 activation, binds to the TRPV1 capsaicin binding site, moderately affects pH-induced TRPV1 gating, and does not alter voltage- or heat-mediated TRPV1 responses. AG1529 suppresses TRPV1-mediated neuronal excitability, reduces capsaicin- and pH-evoked neuronal firing, abolishes histaminergic and inflammation-mediated TRPV1 sensitization. AG1529 exhibits anti-nociceptive and antipruritic effects, attenuates in vivo hyperalgesia and pruritus, dose-dependently reduces acute histaminergic itch in rodents, and mildly blocks hTRPA1 and hTRPM8 channel activity. AG1529 undergoes hydrolysis and dermal deactivation, minimizes TRPV1-associated side reactions, does not evoke capsaicin-like burning sensation, and does not disrupt physiological thermal regulation. AG1529 can be used for the research of inflammatory cutaneous nociception and acute histaminergic pruritus.

For research use only. We do not sell to patients.

AG1529

AG1529 Chemical Structure

CAS No. : 2225980-49-2

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

AG1529 Related Antibodies

Top Publications Citing Use of Products

View All TRP Channel Isoform Specific Products:

View All Isoforms
TRPA1 TRPC3 TRPC4 TRPC5 TRPC6 TRPC7 TRPM8 TRPM2 TRPM3 TRPM4 TRPM7 TRPML1 TRPML2 TRPML3 TRPV1 TRPV2 TRPV3 TRPV4 TRPV6

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

AG1529 is a TRPV1 inhibitor and capsaicinoid-based soft agent with a human TRPV1 IC50 of 0.9-0.93 μM. AG1529 reversibly blocks capsaicin-evoked TRPV1 activation, binds to the TRPV1 capsaicin binding site, moderately affects pH-induced TRPV1 gating, and does not alter voltage- or heat-mediated TRPV1 responses. AG1529 suppresses TRPV1-mediated neuronal excitability, reduces capsaicin- and pH-evoked neuronal firing, abolishes histaminergic and inflammation-mediated TRPV1 sensitization. AG1529 exhibits anti-nociceptive and antipruritic effects, attenuates in vivo hyperalgesia and pruritus, dose-dependently reduces acute histaminergic itch in rodents, and mildly blocks hTRPA1 and hTRPM8 channel activity. AG1529 undergoes hydrolysis and dermal deactivation, minimizes TRPV1-associated side reactions, does not evoke capsaicin-like burning sensation, and does not disrupt physiological thermal regulation. AG1529 can be used for the research of inflammatory cutaneous nociception and acute histaminergic pruritus[1][2].

IC50 & Target[1]

TRPV1

0.93 μM (IC50)

In Vitro

AG1529 (1-100 μM) potently antagonizes TRPV1 in SH-SY5Y cells stably expressing TRPV1 with an IC50 of 0.93 μM[1].
AG1529 is highly stable in HaCaT homogenate (25 μM; 240 min), moderately stable in human plasma (100 μM; 20 min), and completely hydrolyzed in human liver S9 fraction (50 μM; 60 min) under the tested conditions[1].
AG1529 (50 μM; 120 min) is significantly hydrolyzed in primary adult human epidermal keratinocyte and dermal fibroblast homogenates, with only 22.6% and 13.3% residual substrate remaining after 120 min, respectively[1].
AG1529 (0.2 mg/mL) is hydrolyzed by both hCE1 and hCE2, with preferential metabolism by hCE2 as indicated by its higher intrinsic clearance and shorter half-life with this isoform[1].
AG1529 (1 μM) reversibly and competitively blocks capsaicin-activated hTRPV1 in HEK293 cells with an IC50 of 0.9 μM[2].
AG1529 (1-10 μM; 30 s) moderately blocks pH-induced activation of hTRPV1 in HEK293 cells at 10 μM, but does not significantly affect voltage- or heat-mediated hTRPV1 gating at tested concentrations[2].
AG1529 (10 μM; 30 s) moderately inhibits menthol-activated hTRPM8 and AITC-activated hTRPA1 in HEK293 cells at 10 μM, with significantly lower efficacy than its inhibition of hTRPV1[2].
AG1529 binds to the capsaicin binding site of TRPV1 in a conformation similar to capsaicin, supporting its mechanism as a competitive TRPV1 antagonist, while steric hindrance in TRPA1 reduces its binding affinity for that channel[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

AG1529 Related Antibodies
Parmacokinetics
Species Dose Route T1/2 Tmax Cmax AUClast AUCinf
Mice[2] 5 mg/kg i.v. 3.6 min 5.0 min 738.1 ng/mL 14709.3 min·ng/mL 14728.5 min·ng/mL
In Vivo

AG1529 (10-100 μg; i.pl.; single dose) produces a transient, dose-dependent reversal of CFA-induced thermal hyperalgesia without affecting contralateral thermal nociception[1].
AG1529 (1-10 mg/kg; i.v.; single dose) produces a transient, dose-dependent reversal of CFA-induced thermal hyperalgesia without affecting contralateral thermal nociception[1].
AG1529 (100 μg; i.pl.; single dose; 30 minutes prior to histamine) significantly reduces histaminergic pruritus in mice, with peak effects observed 10-20 minutes after histamine injection[1].
AG1529 (100 μg; i.pl.; single dose; 30 minutes prior to chloroquine) significantly reduces non-histaminergic pruritus in mice, with peak effects observed 5-15 minutes after chloroquine injection[1].
AG1529 (10 mg/kg; i.v.; single dose) does not affect body temperature in mice, avoiding the hyperthermia side effect associated with other TRPV1 antagonists[1].
AG1529 (0.1-1% w/v; topical wipe; single application) dose-dependently reduces histamine-induced pruritus in rats, with 1% AG1529 producing the greatest attenuation of scratching behavior[2].
AG1529 (0.1-1% w/w; topical application; twice daily; 3 days) significantly reduces histamine-induced pruritus in rats, with 1% AG1529 completely eliminating scratching behavior[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: unspecified[1]
Dosage: 10 μg; 30 μg; 100 μg
Administration: i.pl.; single dose
Result: Ablated CFA-induced thermal hyperalgesia in the ipsilateral paw in a dose-dependent and transient manner.
Showed anti-hyperalgesic activity at 30 minutes, peaked at 60 minutes, and lasted for 90 minutes at the 100 μg dose.
Did not affect thermal nociception in the contralateral paw.
Animal Model: unspecified[1]
Dosage: 1 mg/kg; 3 mg/kg; 10 mg/kg
Administration: i.v.; single dose
Result: Attenuated CFA-induced thermal hyperalgesia in the ipsilateral paw in a dose-dependent and transient manner.
Showed anti-hyperalgesic effects at 30 minutes, lasting 60 minutes at the 1 mg/kg dose.
Showed effects at 60 minutes, lasting 90 minutes at the 3 mg/kg dose.
Showed significant effects only at 60 minutes at the 10 mg/kg dose.
Did not affect thermal nociception in the contralateral paw.
Animal Model: unspecified[1]
Dosage: 100 μg
Administration: i.pl.; single dose; 30 minutes prior to histamine
Result: Attenuated histamine-induced paw licking time, with statistically significant reductions in the 10-15 minute and 15-20 minute intervals after histamine instillation.
Animal Model: unspecified[1]
Dosage: 100 μg
Administration: i.pl.; single dose; 30 minutes prior to chloroquine
Result: Reduced chloroquine-induced paw licking time, with statistically significant reductions in the 5-10 minute and 10-15 minute intervals after chloroquine instillation.
Animal Model: unspecified[1]
Dosage: 10 mg/kg
Administration: i.v.; single dose
Result: Did not alter mouse body temperature over the 120-minute observation period, unlike the positive control TRPV1 antagonist BCTC which induced significant hyperthermia.
Animal Model: Wistar (adult, 100-125 g, pruritus model via subcutaneous histamine injection)[2]
Dosage: 0.1% w/v; 1% w/v
Administration: topical wipe; single application
Result: Significantly reduced histamine-induced licking time across all 10-minute intervals from 0-60 minutes post-histamine injection.
Produced a dose-dependent reduction in total scratching counts over 60 minutes: 0.1% AG1529 reduced scratching compared to vehicle (p = 0.0003), and 1% AG1529 produced an even greater reduction (p < 0.0001 vs vehicle; p = 0.0395 vs 0.1% AG1529).
Animal Model: Wistar (adult, 100-125 g, pruritus model via subcutaneous histamine injection)[2]
Dosage: 0.1% w/w; 1% w/w
Administration: topical application; twice daily; 3 days
Result: Significantly reduced histamine-induced licking time across all 10-minute intervals from 0-60 minutes post-histamine injection, with the 1% dose nearly eliminating licking activity in most intervals.
Reduced total scratching counts over 60 minutes: 0.1% AG1529 reduced scratching compared to vehicle (p = 0.0122), and 1% AG1529 fully abrogated scratching behavior (p = 0.0003 vs vehicle).
Molecular Weight

519.41

Formula

C22H34INO5
CAS No.
SMILES

O=C(CCCCCCCCCCC)OCC(NCC1=C(I)C=C(O)C(OC)=C1)=O
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

AG1529 Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

AG15292225980-49-2AG 1529AG-1529TRP ChannelTransient receptor potential channelshuman liver S9 fractiondermal fibroblastTRPV1hCE2human epidermal keratinocytecapsaicinSH-SY5Y cellshCE1human plasmaHaCaTInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
AG1529
Cat. No.:
HY-182517
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.